Myristoleic Acid

立即咨询

Myristoleic Acid

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	544-64-9
规格:	≥98%

包装与价格：

包装	价格(元)
50mg	电议
100mg	电议
250mg	电议
500mg	电议

产品介绍

理化性质和储存条件

Molecular Formula: C14H26O2;

Exact Mass: 226.1933;

Molecular Weight: 226.36

Synonym: cis-9-Tetradecenoate; Myristoleic Acid; Oleomyristic Acid

Chemical Name: (Z)-tetradec-9-enoic acid

InChi Key: YWWVWXASSLXJHU-WAYWQWQTSA-N

InChi Code: InChI=1S/C14H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h5-6H,2-4,7-13H2,1H3,(H,15,16)/b6-5-

SMILES Code: OC(CCCCCCC/C=C\CCCC)=O

In Vitro	Myristoleic acid (cis-9-Tetradecenoate; Oleomyristic Acid) induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells[1]. Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation[2]. Cell Proliferation Assay[1] Cell Line: Human prostatic carcinoma LNCaP cells. Concentration: 0, 50, 100, 150, 200, 250 μg/mL. Incubation Time: 24 h. Result: When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively.
In Vivo	Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice[2]. Animal Model: C57BL/6 mice at 5 weeks[2]. Dosage: 0.2, 2 mg/kg Administration: IP every 24 h for 4 days. Result: Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner.

In Vitro

Myristoleic acid (cis-9-Tetradecenoate; Oleomyristic Acid) induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells[1]. Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation[2]. Cell Proliferation Assay[1] Cell Line: Human prostatic carcinoma LNCaP cells. Concentration: 0, 50, 100, 150, 200, 250 μg/mL. Incubation Time: 24 h. Result: When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively.

In Vivo

Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice[2]. Animal Model: C57BL/6 mice at 5 weeks[2]. Dosage: 0.2, 2 mg/kg Administration: IP every 24 h for 4 days. Result: Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner.